Probiotics under the regulatory microscope

Bibliography

• VAUGHAN EE, SCHUT F, HEILIG HGHJ, ZOETENDAL EG, DE VOS WM, AKKERMANS ADL: A molecular view of the intestinal ecosystem. Curr. Issues Intest. Microbiol (2000) 1:1–12.
   PubMedGoogle Scholar
• AKKERMANS ADL, ZOETNDAL EG, FAVIER CF et al.: Temperature and denaturing gradient gel electrophoresis analysis of 16S rRNA from human faecal samples. Biosci Microflora (2000) 19:93–98.
   Google Scholar
• CLANCY R: Immunobiotics and the probiotic evolution. FEMS Immunol. Med. Microbiol (2003) 38:9–12.
   PubMed Web of Science ®Google Scholar
• •This article identifies a creeping change in probiotic usage and understanding, Initiating a new direction for use and giving a comprehensive framework for understanding process.
   Google Scholar
• ROOS K, HAKANSSON EG, HOLM S: Effect of recolonisation with 'interfering' a streptococci on recurrences of acute and secretory otitis media in children: randomized placebo controlled trial. Br. Med. J. (2001) 322:210.
   PubMed Web of Science ®Google Scholar
• ••This is an important clinical study thatmoves 'probiotic usage' into a new region and opens up an exciting range of directions. It also asks questions of toxicity of another type — immune cross-reaction.
   Google Scholar
• MACFARLANE GT, CUMMINGS JH: Probiotics and probiotics: can regulating the activities of intestinal bacteria benefit health? BE Med. J. (1999) 318:999–1003.
   Google Scholar
• DUNNE C, MURPHY L, FLYNN S et al: Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek (1999) 76:279–292.
   Google Scholar
• O'MAHONY L, McCARTHY J, KELLY Pet al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterol (2005) 128:541–551.
   Google Scholar
• •The Cork team take IBS and probiotics to a new level by demonstrating cytokine changes that link with clinical benefit. This means future studies need to include surrogate markers.
   Google Scholar
• ISOLAURI E, JUNTUNEN M, SAXILIN M, VESIKARI T: Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J. Pediatr. Gastroenterol (1995) 20:333–336.
   PubMed Web of Science ®Google Scholar
• KALLIOMAKI M, SALMINEN S, ARVILOMMI H, KERO P, KOSKINEN P, ISOLAURI E: Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet (2001) 357:1076–1079.
   PubMed Web of Science ®Google Scholar
• •This important clinical study is one of several by this group, validating new roles for probiotics — also demonstrating need to consider toxicology in terms of a different range of mechanisms.
   Google Scholar
• WOLD AE: Immune effects of probiotics. Scandj Nutr. (2001) 45:76–85.
   Google Scholar
• SOLIS B, NOVAE, GOMEZ S et al: The effect of fermented milk on interferon production in malnourished children and in anorexia nervosa patients undergoing nutritional care. Eur. j Ciln. Nutr. (2002) 56\(Suppl. 4):S27–S33.
   Google Scholar
• POHJAVUORI E, VILJANEN M, KORPELA R et al.: Lactobacillus GG effect in increasing IFN-y production in infants with cow's milk allergy I Allergy Clin. Irrununol. (2004) 114:131–136.
   Web of Science ®Google Scholar
• D'OSTIANI CE DEL SER G, BACCI A et al.: Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans: implications for initiation of T helper cell immunity in vitro and in vivo. J. Exp. Med. (2000) 191:1661–1678.
   Google Scholar
• KADOWAKI N, HO S, ANTONENKO A et al.: Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. Exp. Med. (2001) 194:863–869.
   PubMed Web of Science ®Google Scholar
• HESSLE C, ANDERSSON B, WOLD AE: Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while Gram-negative bacteria preferentially stimulate IL-10 production. Infect. Irrunun. (2000) 68:3581–3586.
   PubMed Web of Science ®Google Scholar
• HART AL, LAMMERS K, BRIGIDI P et al.: Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 53(11):1602–1609.
   PubMed Web of Science ®Google Scholar
• RUDZIK R, CLANCY RL, PEREY DYE, DAY RP, BIENENSTOCK J: Repopulation with IgA containing cells of bronchial and intestinal lamina propria after transfer of homologous Peyer's patch and bronchial lymphocytes. I Inrinuno] (1975) 114(5):1599–1604.
   Google Scholar
• ELAHI S, PANG G, CLANCY R, ASHMAN RB: Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis. Infect. Inrinun. (2000) 68:5771–5777.
   PubMed Web of Science ®Google Scholar
• •The value of this animal model is that the mechanisms are clearly defined, and thus intervention therapy with L. acidophilus operates through well-understood processes.
   Google Scholar
• ELAHI S, PANG G, CLANCY R: Development of surrogate markers for oral immunization against Candida albicans. Vaccine (2002) 3526:1–7.
   Google Scholar
• REID G, BRUCE AW, FRASER N, HEINEMANN C, OWEN J, HENNING B: Oral probiotics can resolve urogenital infections. FEMS Med. Microbiol. (2001) 30:49–52.
   PubMed Web of Science ®Google Scholar
• CLANCY R, PANG G, JUN YU D, ELAHI S, DUNKLEY M: The management of mucosal dysregulation using Lactobacillus acidophilus (Lavri-1). Allergy Clin. Iminuno] Int. I World. Allergy Org. (2004) Suppl. 1:283–286.
   Google Scholar
• SLY P, HOLT P: Etiological factors of atopic disease in the respiratory tract. Mucosa] Iminunol. (1999) Update 7:13–14.
   Google Scholar
• METCHNIKOFF E: The prolongation of life: Optimistic studies. Heinemann, London, 1907.
   Google Scholar
• WUNDERLICH PF, BRAUN L, FUMAGALLI I et al.: Double blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J. Int. Med. Res. (1989) 17:333–338.
   PubMed Web of Science ®Google Scholar
• BELLOMO G, MANGIAGLE A, NICASTRO I et al : A controlled double blind study of SF68 strain as a new biological preparation for the treatment of diarrhoea in paediatrics. Curr. Ther. Res. (1980) 28:927–936.
   Web of Science ®Google Scholar
• Huang JS, BOUSVAROS A, LEE JW, DIAZ A, DAVIDSON EJ: Efficacy of probiotic use in acute diarrhoea in children: a meta-analysis. Dig. Dis. Sci. (2002) 47:2625–2634.
   PubMed Web of Science ®Google Scholar
• ISOLAURI E, KAILA M, MYKAKANEN H, LING WH, SALMINEN S: Oral bacteriotherapy for viral gastroenteritis. Dig. Dis. Sci. (1994) 39:2595–2600.
   PubMed Web of Science ®Google Scholar
• ISOLAURI E, JUNTUNEN M, SAXILIN M, VESIKARI T: Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J. Pediatr. Castroenterol. (1995) 20:333–336.
   PubMed Web of Science ®Google Scholar
• KRUIS W, ERIC P, POKROTNIEKS J et al.: Maintaining remission of ulcerative colitis with the probiotic E coliNissle 1917 is as effective as with standard mesalazine. Cut (200 4) 53:1617–1623.
   Google Scholar
• REMBACKEN BJ, SNELLING AM, HAWKEY PM, CHALMERS DM, AXON AT: Non-pathogenic E cob versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 354:635–639.
   PubMed Web of Science ®Google Scholar
• KRUIS W, ERIC P, POKROTNIEKS J, LUKAS M, JUDMAIER G, STOLTE M: Double blind comparison of an oral Escherichia cob preparation and mesalazine in maintaining remission of ulcerative colitis. Ailment Phannacol. Ther. (1997) 11:853–858.
   PubMed Web of Science ®Google Scholar
• GIONCHETTI P, RIZELLO F, VENTURI A et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo-controlled trial. Castroenterol. (2000) 119:305–309.
   PubMed Web of Science ®Google Scholar
• •An important clinical study that moves probiotic usage into the medical arena In potentially serious medical conditions.
   Google Scholar
• MIMURA T, RIZELLO F, HELWIG U et al: Once daily high dose probiotic therapy (VSL3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 53:108–114.
   PubMed Web of Science ®Google Scholar
• FED ORAK RN, GIONCHETTI P, CAMPIERI M et al.: Probiotic mixture induces remission in patients with ulcerative colitis. Castroenterol (2003) 124:A377.
   PubMed Web of Science ®Google Scholar
• BORODY TJ, WARREN EF, LEIS SM, SURACE R, ASHMAN O, SIARAKAS S: Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Castroenterol (2004) 38:475–483.
   PubMed Web of Science ®Google Scholar
• ••A review of an area in probiotic therapythat has challenged everyone. It identifies a new platform of potential 'toxicity' and although effective, in a sense reverses current scientific trends.
   Google Scholar
• BORODY TJ, WARREN EF, LEIS S, SURACE R, ASHMAN O: Treatment of ulcerative colitis using fecal bacteriotherapy. J. Chi]. Castroenterol (2003) 37:42–47.
   PubMed Web of Science ®Google Scholar
• PRANTERA C, SCRIBANO ML, FALASCO G, ANDREOLI A, LUZI C: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut (2002) 51:405–409.
   PubMed Web of Science ®Google Scholar
• MALCHOW HA: Crohn's disease and E coli. A new approach in therapy to maintain remission in colonic Crohn's disease? J. Chi]. Castroenterol (1997) 25:653–658.
   Google Scholar
• GUANDALINI S. Use of Lactobacillus-GG in paediatric Crohn's disease. Dig. Liver Dis. (2002) 34\(Suppl. 2):563–565.
   Google Scholar
• SHANAHAN F: Host-Flora interactions in inflammatory bowel disease. Inflam. Bowel Dis. (2004) 10\(Suppl. 1):S16–S28.
   Google Scholar
• NOBAEK S, JOHANSSON ML, MOLIN G, AHME S, JEPPSSON B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. .1. Gastroenterol (2000) 95:1231–1238.
   PubMed Web of Science ®Google Scholar
• NIEDZIELIN K, KORDECKI H, BIRKENFELD B: A controlled, double blind, randomised study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. I Castroenterol Hepatol (2001) 13:1143–1147.
   PubMed Web of Science ®Google Scholar
• BORODY TJ, GEORGE L, ANDREW PJ et al.: Bowel flora alteration: potential cure for inflammatory bowel disease and irritable bowel syndrome? Med. J. Aust. (1989) 150:604.
   PubMed Web of Science ®Google Scholar
• EISENMAN B, SILEN W, BASCOM GS, KAUVAR AJ: Fecal enema as an adjunct in the treatment of pseudomembraneous enterocolitis. Surgery (1958)44:854–859.
   PubMed Web of Science ®Google Scholar
• PERSKY SE, BRANDT LJ: Treatment of recurrent Clostridium chficlle-associated diarrhoea by administration of donated stool directly through a colonoscope. Am. J. Castroenterol (2000) 95:3283–3285.
   PubMed Web of Science ®Google Scholar
• BORIELLO SP, HAMMES WP, HOLZAPFEL W et al: Safety of probiotics that contain lactobacilli or bifidobacteria. Clin. Infect. Dis. (2003) 36:775–780.
   PubMed Web of Science ®Google Scholar
• FONDEN R, MOGENSEN G, TANAKA R, SALMINEN S: Culture-containing dairy products - effect on intestinal microflora, human nutrition and health - current knowledge and future perspectives. Brussels: International Dairy Federation (2000). Report No. IDF352.
   Google Scholar
• LEDUC H, HONG HA, BARBOSA TM, HENRIQUES AO, CUTTING SM: Characterization of Bacillus probiotics available for human use. Appl. Environ. Microbiol (2004) 70(4):2161–2171.
   PubMed Web of Science ®Google Scholar
• BUTS J-P, CORTHIER G, DELMEE M:Saccharomyces boulardii for Clostridium dificlle-associated enteropathies in infants. Pediatr. Castroenterol Nub: (1993) 16:419–425.
   PubMed Web of Science ®Google Scholar
• KRUIS W, FRIC P, POKROTNIEKS J et al.: Maintaining remission of ulcerative colitis with the probioitic Escherichia cob Nissle 1917 is as effective as with standard mesalazine. Cut (2004) 53(10:1617–1623.
   Google Scholar
• ANDREWS PJ, BARNES P, BORODY TJ: Chronic constipation reversed by restoration of bowel flora. A case and a hypothesis. Eur. Castroenterol Hepatol (1992) 4:245–247.
   Web of Science ®Google Scholar
• ANDREWS PJ, BORODY TJ: 'Putting back the bugs': bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med. J. Aust. (1993) 159(9):633–634.
   PubMed Web of Science ®Google Scholar
• RICHARD V, AUWERA P, SNOECK R, DANEAU D, MEUNIER F: Nosocomial bacteremia caused by Bacillus species. Eur. Clin. Infect. Dis. (1988) 7:783–785.
   PubMed Web of Science ®Google Scholar
• OGGIONI MR, POZZI G, GALIENI PE,BIGAZZI C: Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. Microbiol (1998) 36:325–326.
   Web of Science ®Google Scholar
• SPINOSA MR, WALLET F, COURCOL RJ, OGGIONI MR: The trouble in tracing opportunistic pathogens: cholangitis due to Bacillus in a French hospital caused by a strain related to an Italian probiotic. Microb. Era Health Dis. (2000) 12:99–101.
   Google Scholar
• HARTY DWS, PATRIKAKIS M, KNOW KW: Identification of Lactobacillus strains isolated from patients with infective endocarditis and comparison of their surface-associated properties with those of other strains of the same species. Microb. Era Health Dis. (1993) 6:191–201.
   Web of Science ®Google Scholar
• GRIFFITHS JK, DALY JS, DODGE RA:Two cases of endocarditis due to Lactobacillus species: antimicrobial susceptibility, review, and discussion of therapy. Clin. Infect. Dis. (1992) 15(2):250–255.
   PubMed Web of Science ®Google Scholar
• MONTERISI A, DAN AA, SUAREZ-DE-BASNEC MC, ROCA G, TRUCCHIA R, BANTAR C: Native-valve endocarditis produced by bactobacillus rhamnosus refractory to microbial therapy. Medicine (1996) 56(3):284–286.
   Google Scholar
• KIRJAVAINEN PV, TUOMOLA EM, CRITTENDEN RG et al: In vitro adjesion and platelet aggregation properties of bacteremia-associated lactobacilli. Infect. Immun. (1999) 67(5):2653–2655.
   PubMed Web of Science ®Google Scholar
• DYSON C, BARNES RA, HARRISON GA: Infective endocarditis: an epidemiological review of 128 episodes. Infect. (1999) 38(2):87–93.
   Web of Science ®Google Scholar
• SALMINEN MK, JARVINEN A, SAXELIN M, TYNKKYNEN S, RAUTELIN H, VALTONEN V: Increasing consumption of Lactobacillus GG as a probiotic and the incidence of lactobacilli bacteremia in Finland. Chi]. Microbiol Infect. (2001) 7\(Suppl. 1):802.
   Google Scholar
• •An important Scandinavian study that, although giving comfort, keeps the potential of septicaemic complications In vision.
   Google Scholar
• BONGAERTS GP, TOLBOOM JJ, NABER AH et al.: Role of bacteria in the pathogenesis of short bowel syndrome-associated D-lactic acidemia. Microb. Pathog. (1997) 22(5):285–293.
   PubMed Web of Science ®Google Scholar
• KANEKO T, BANDO Y, KURIHARA H, SATOMI K, NONOYAMA K, MATSUURA N: Fecal microflora in a patient with short-bowel syndrome and identification of dominant lactobacilli. Chi]. Microbiol (1997) 35(12):3181–3185.
   Web of Science ®Google Scholar
• BONGAERTS G, BAKKEREN J, SEVERIJNEN R et al: Lactobacilli and acidosis in children with short small bowel. Pediatr. Castroenterol Nutr. (2000) 30(3):288–293.
   PubMed Web of Science ®Google Scholar
• HOWARD FM, RAY RM, SHOFF R et al: Fecal bile acids in two Japanese populations with different colon cancer risks. Cancer Res. (1974) 39:328–331.
   Google Scholar
• LAPIERRE L, GERMOND JE, OTT A, DELLEY M, MOLLET B: D-Lactate dehydrogenase gene (1 dhD) inactivation and resulting metabolic effects in the Lactobacillus johnsonii strains Lal and N312. Appl. Environ. Microbiol (1999) 65(9):4002–4007.
   PubMed Web of Science ®Google Scholar
• SAARELA M, MOGENSEN G, FONDEN R, MATTO J, MATTILA-SANDHOLM T: Probiotic bacteria: safety, functional and technological properties. I Biotechnol (2000) 84:197–215.
   Google Scholar
• TEUBER M, MEILE L, SCHWARZ F: Acquired antibiotic resistance in lactic acid bacteria from food. Antonie van Leeuwenhoek (1999) 76:115–137.
   PubMed Web of Science ®Google Scholar
• SALYERS AA, GUPTA A, WANG Y: Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol (2004) 12(9):412–416.
   PubMed Web of Science ®Google Scholar
• •The big unanswered question. Gene shuttling will occur, and must be anticipated.
   Google Scholar
• CHARTERIS WP, KELLY PM, MORELLI L, COLLINS JK: Antibiotic susceptibility of potentially probiotic Lactobacillus strains. I Food Protect. (1998) 61(12):1636–1643.
   PubMed Web of Science ®Google Scholar
• KLEIN G, HALLMANN C, CASAS IA, ABAD J, LOUWERS J, REUTER G: Exclusion of vanA, vanB and vanC type glycopeptide resistance in strains of Lactobacillus reuteri and Lactobacillus rhamnosus used as probiotics by polymerase chain reaction and hybridisation methods. Appl. Microbiol (2000) 89:815–824.
   Google Scholar
• TEMMERMAN R, POT B, HUYS G, SWINGS J: Identification antibiotic susceptibility of bacterial isolates from probiotic products. Int. J. Food MicroPro]. (2003) 81(1):1–10.
   PubMed Web of Science ®Google Scholar
• TYNKKYNEN S, SINGH K, VARMANEN P: Vancomycin resistance factor in Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Lit. J. Food Microbial. (1998) 41:195–204.
   PubMed Web of Science ®Google Scholar
• FAO/WHO: Guidelines for the evaluationof probiotics in food. London, Ontario, Canada (2002) 1 May.
   Google Scholar
• SCIENTIFIC COMMITTEE ON ANIMAL NUTRITION (SCAN): Opinion of the Scientific Committee on Animal Nutrition on the criteria for assessing the safety of micro-organisms resistant to antibiotics of human clinical and veterinary importance (adopted on 3 July 2001, revised on 18 April 2002).
   Google Scholar
• •A start regarding guidelines, but traditional approach needs to be modernised.
   Google Scholar